Advisors Management Group Inc. ADV Sells 173 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

by · The Markets Daily

Advisors Management Group Inc. ADV lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 0.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,134 shares of the biopharmaceutical company’s stock after selling 173 shares during the quarter. Advisors Management Group Inc. ADV’s holdings in Gilead Sciences were worth $2,862,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Manning & Napier Advisors LLC purchased a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $25,328,000. Legal & General Group Plc grew its stake in Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after purchasing an additional 93,068 shares during the period. IRON Financial LLC bought a new position in Gilead Sciences in the third quarter worth $830,000. GSA Capital Partners LLP purchased a new position in Gilead Sciences during the first quarter valued at $462,000. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Gilead Sciences by 13.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock valued at $19,630,000 after buying an additional 33,162 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on GILD shares. Truist Financial lifted their price target on shares of Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Cantor Fitzgerald reissued a “neutral” rating and issued a $70.00 price target on shares of Gilead Sciences in a research report on Monday, September 16th. Wells Fargo & Company raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $78.00 to $100.00 in a research report on Monday, October 7th. BMO Capital Markets lifted their price objective on Gilead Sciences from $85.00 to $94.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Finally, JPMorgan Chase & Co. increased their target price on Gilead Sciences from $95.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 9th. Ten research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.85.

Read Our Latest Research Report on Gilead Sciences

Gilead Sciences Stock Up 1.6 %

Shares of GILD stock opened at $91.69 on Thursday. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $91.98. The stock has a market cap of $114.15 billion, a P/E ratio of 111.82, a P/E/G ratio of 3.13 and a beta of 0.17. The company has a 50 day simple moving average of $84.58 and a two-hundred day simple moving average of $74.67.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The company had revenue of $6.95 billion for the quarter, compared to analysts’ expectations of $6.64 billion. On average, research analysts expect that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,847 shares of company stock valued at $3,033,340 over the last quarter. 0.29% of the stock is currently owned by company insiders.

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Read More